{
  "abstract": "Liver disease represents a major global health challenge and encompasses a spectrum of disorders including steatotic liver diseases (such as alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD)), viral hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. These disorders arise from diverse aetiologies but converge on common pathological mechanisms, including chronic hepatocellular injury, immune dysregulation, inflammation and progressive fibrotic remodelling. Sustained inflammatory signalling promotes extracellular matrix deposition, architectural distortion and loss of hepatic metabolic and detoxification capacity. As the disease advances, complications such as portal hypertension, ascites, hepatic encephalopathy and liver failure may develop. Despite improvements in palliative care and disease management, effective therapies that directly target disease-driving mechanisms in steatotic liver disease remain limited.1 A deeper understanding of interorgan communication pathways that regulate hepatic inflammation is therefore essential for the development of innovative therapeutic strategies.2",
  "authors": [
    {
      "affiliations": [
        "Independent Researcher, Arvada, Colorado, USA"
      ],
      "name": "Rachel Yue Gao"
    }
  ],
  "title": "Targeting gut immunity as a therapy for steatotic liver disease",
  "uid": "44dbee5b-bb18-5009-8ef5-56c5d7929594"
}